Metabolic Health Protocol

Overview

Metabolic health encompasses a broad range of physiological parameters including insulin sensitivity, glucose homeostasis, lipid metabolism, mitochondrial function, and energy expenditure. Dysfunction in these systems underlies conditions such as metabolic syndrome, type 2 diabetes, and obesity — conditions that have become increasingly prevalent worldwide.

Peptide-based approaches to metabolic health target multiple nodes in these interconnected systems. Rather than relying on a single mechanism, this protocol combines compounds that address incretin signaling (GLP-1 receptor agonists), mitochondrial-derived signaling (MOTS-c), and growth hormone fragment-mediated lipolysis (AOD-9604).

The rationale for a multi-compound approach is that metabolic dysfunction is rarely attributable to a single pathway. Insulin resistance, impaired mitochondrial function, and dysregulated fat metabolism often coexist and reinforce each other. Addressing multiple pathways simultaneously may produce more comprehensive metabolic improvement than targeting any single mechanism alone.

Compounds Involved

Protocol Structure

This protocol is structured with a gradual introduction of compounds and careful dose titration, particularly for GLP-1 receptor agonists which require slow upward titration to manage gastrointestinal side effects.

Phase 1: GLP-1 Foundation (Weeks 1–8)

The cornerstone of the metabolic health protocol is the GLP-1 receptor agonist, introduced first to establish incretin-mediated metabolic improvement.

Semaglutide (if using as the GLP-1 agent):

• Starting dose: 0.25 mg per week for 4 weeks
• Titration: Increase to 0.5 mg per week for weeks 5–8
• Further titration: 1.0 mg per week from week 9, up to 2.4 mg per week as tolerated
• Frequency: Once weekly, same day each week
• Injection site: Abdominal subcutaneous, rotating sites
• Timing: No specific fasting requirement

For Tirzepatide, a dual GIP/GLP-1 receptor agonist, the titration schedule follows a similar stepwise approach starting at 2.5 mg weekly. See the Weight Management Protocol for detailed GLP-1 agonist comparison.

Phase 2: MOTS-c Addition (Weeks 5–12)

Once the GLP-1 foundation is established, MOTS-c is introduced to support mitochondrial function and AMPK-mediated glucose metabolism.

MOTS-c:

• Dose: 5 mg per injection, working up to 10 mg based on tolerance
• Frequency: 3–5 times per week
• Injection site: Subcutaneous, abdominal
• Timing: Morning administration is common, often before exercise on training days
• Rationale: MOTS-c acts as a mitochondrial-derived peptide that activates AMPK, the master energy-sensing kinase. This complements GLP-1 signaling by addressing cellular energy metabolism directly

Phase 3: AOD-9604 Integration (Weeks 5–12)

AOD-9604, a modified fragment of growth hormone (amino acids 176-191), is added to support lipolysis without the metabolic complications associated with full-length growth hormone.

AOD-9604:

• Dose: 300 mcg per day (can be increased to 600 mcg, split into two doses)
• Frequency: Once or twice daily
• Injection site: Subcutaneous, abdominal (some administer near target fat deposits, though systemic effects may be equivalent)
• Timing: Fasted state preferred — typically morning before breakfast
• Rationale: AOD-9604 stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from GH receptor activation, meaning it does not produce the insulin resistance or glucose elevation associated with exogenous growth hormone

Phase Summary Table

Metabolic Monitoring

Objective measurement is essential for evaluating protocol response. Key biomarkers to track include:

• Fasting glucose and insulin: Baseline and monthly. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) can be calculated from these values
• HbA1c: Reflects average glucose over 2–3 months. Assess at baseline and at protocol completion
• Lipid panel: Total cholesterol, LDL, HDL, triglycerides. GLP-1 agonists have shown favorable effects on lipid profiles in clinical research
• Body composition: DEXA scan or equivalent at baseline and at weeks 8 and 12
• Inflammatory markers: hsCRP and fasting insulin provide indirect measures of metabolic inflammation
• Liver enzymes: ALT and AST, as metabolic improvement often correlates with improved liver function

Important Considerations

• GLP-1 titration is not optional: Rapid dose escalation of semaglutide or tirzepatide produces significant nausea, vomiting, and gastrointestinal distress. The slow titration schedule exists for tolerability and should be followed strictly.
• Gastrointestinal side effects: Nausea, constipation, and reduced appetite are common with GLP-1 agonists, particularly during dose increases. These typically attenuate over 2–4 weeks at each dose level.
• Contraindications for GLP-1 agonists: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindications identified in clinical trials. A history of pancreatitis warrants caution.
• Exercise amplifies MOTS-c effects: Research suggests MOTS-c and exercise activate overlapping metabolic pathways. Combining MOTS-c administration with regular exercise may produce synergistic metabolic benefits.
• AOD-9604 does not affect blood glucose: Unlike full-length growth hormone, AOD-9604 does not impair glucose metabolism. This makes it compatible with the insulin-sensitizing goals of this protocol.
• Caloric intake still matters: GLP-1 agonists reduce appetite, which naturally decreases caloric intake. However, intentional nutritional planning ensures adequate protein and micronutrient intake during periods of reduced appetite.
• Hydration: GLP-1 agonists can cause dehydration through reduced fluid intake (diminished thirst signals) and gastrointestinal side effects. Deliberate hydration is important.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.